Daiwa Securities Group Inc. Has $1.08 Million Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Daiwa Securities Group Inc. increased its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 6.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,549 shares of the medical research company’s stock after acquiring an additional 265 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Charles River Laboratories International were worth $1,075,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in CRL. Boston Trust Walden Corp lifted its stake in shares of Charles River Laboratories International by 0.5% in the third quarter. Boston Trust Walden Corp now owns 190,897 shares of the medical research company’s stock worth $37,412,000 after acquiring an additional 869 shares during the period. Norris Perne & French LLP MI lifted its stake in Charles River Laboratories International by 1.0% in the third quarter. Norris Perne & French LLP MI now owns 103,890 shares of the medical research company’s stock valued at $20,360,000 after buying an additional 1,077 shares during the period. Czech National Bank lifted its stake in Charles River Laboratories International by 47.9% in the third quarter. Czech National Bank now owns 8,961 shares of the medical research company’s stock valued at $1,756,000 after buying an additional 2,902 shares during the period. Asset Management One Co. Ltd. lifted its stake in Charles River Laboratories International by 7.7% in the third quarter. Asset Management One Co. Ltd. now owns 20,573 shares of the medical research company’s stock valued at $4,032,000 after buying an additional 1,474 shares during the period. Finally, North Growth Management Ltd. lifted its stake in Charles River Laboratories International by 15.6% in the third quarter. North Growth Management Ltd. now owns 37,000 shares of the medical research company’s stock valued at $7,261,000 after buying an additional 5,000 shares during the period. 98.91% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Stock Down 0.3 %

Shares of NYSE:CRL opened at $239.46 on Thursday. The company has a market capitalization of $12.33 billion, a PE ratio of 26.00, a price-to-earnings-growth ratio of 1.82 and a beta of 1.40. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.52 and a quick ratio of 1.16. The business has a fifty day moving average price of $254.15 and a two-hundred day moving average price of $222.36. Charles River Laboratories International, Inc. has a 1 year low of $161.65 and a 1 year high of $275.00.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.39 by $0.07. The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $991.25 million. Charles River Laboratories International had a return on equity of 16.53% and a net margin of 11.49%. The business’s revenue for the quarter was down 7.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.98 EPS. Analysts forecast that Charles River Laboratories International, Inc. will post 11.01 earnings per share for the current year.

Wall Street Analysts Forecast Growth

CRL has been the subject of several recent research reports. Argus boosted their price objective on Charles River Laboratories International from $240.00 to $290.00 and gave the company a “buy” rating in a report on Monday, March 18th. UBS Group boosted their price objective on Charles River Laboratories International from $270.00 to $290.00 and gave the company a “buy” rating in a report on Thursday, February 15th. JPMorgan Chase & Co. boosted their price objective on Charles River Laboratories International from $270.00 to $280.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. TheStreet upgraded Charles River Laboratories International from a “c+” rating to a “b-” rating in a report on Friday, March 1st. Finally, Guggenheim downgraded Charles River Laboratories International from a “buy” rating to a “neutral” rating in a report on Thursday, February 15th. Five research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, Charles River Laboratories International presently has an average rating of “Moderate Buy” and an average target price of $253.23.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Shannon M. Parisotto sold 5,882 shares of the company’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the transaction, the executive vice president now owns 2,596 shares of the company’s stock, valued at approximately $626,155.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, EVP Victoria L. Creamer sold 5,000 shares of the stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $253.70, for a total transaction of $1,268,500.00. Following the completion of the transaction, the executive vice president now owns 13,550 shares in the company, valued at approximately $3,437,635. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Shannon M. Parisotto sold 5,882 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $241.20, for a total value of $1,418,738.40. Following the transaction, the executive vice president now owns 2,596 shares of the company’s stock, valued at approximately $626,155.20. The disclosure for this sale can be found here. Insiders sold 14,932 shares of company stock worth $3,693,663 in the last quarter. 1.30% of the stock is currently owned by company insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).